HB007 - 10mM in DMSO , CAS No.2387821-46-5

CAS: 2387821-46-5 Cat. No.: H655911 Summenformel: C₁₅H₉ClN₄OS Molekulargewicht: 328.78

QUALITÄT & REINHEIT 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Übersicht

HB007 is a small ubiquitin-related modifier 1 (SUMO1) degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers

In Vitro

HB007 (compound 24) (0.1-100 μM) inhibits LN229 cell growth in a concentration-dependent manner t. HB007 (10-25 μM) reduces SUM01 conjugation and total protein levels of SUM01 but not SUM02/3 or UB in LN229 cells t. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

HB007 (compound 24) (25-50 mg/kg; i.p. for 15 d) significantly suppresses tumor growth of colon and lung cancer but had no effect on the body weights of mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:SUMO1

Spezifikationen

Spezifikationen & Reinheit

10mM in DMSO

Biochemische und physiologische Mechanismen

HB007 is a small ubiquitin-related modifier 1 (SUMO1) degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers.

Storage

Store at -80°C

Verschickt in

Dry ice packs + Cold packs

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Aktionsart

INHIBITOR

Namen und Kennungen

Molekulargewicht

328.78

Application Protocols

There are no item-specific, validated application protocols provided for HB007 in this listing.

General protocol for preparing screening stocks (research use only):

1. Equilibrate the vial to room temperature in a desiccator before opening to minimize condensation (material is stored at −80 °C).
2. If solid: add anhydrous DMSO to prepare a 10–50 mM stock. Vortex and, if needed, sonicate briefly. If pre-dissolved: verify concentration on the label/CoA.
3. Inspect for clarity; if particulates remain, centrifuge briefly and transfer the supernatant to a low-bind vial.
4. Aliquot into single-use portions (e.g., 10–50 μL) to avoid freeze–thaw; label with compound ID, lot, concentration, solvent, and date.
5. For dosing, dilute the stock into assay buffer to the desired concentration, ensuring final DMSO ≤0.5–1% v/v. Include vehicle controls.
6. Store working plates at 4 °C during the assay day; discard after use unless stability has been verified.

Analytical QC (recommended):

• Confirm identity/purity by LC–MS upon first use and after prolonged storage to ensure no degradation.

Note: This guidance is generic for small-molecule screening compounds and not specific to HB007’s chemistry.

Biological Roles

Specific biological function, targets, and pathways for HB007 are not disclosed in this catalog record.

General considerations for small-molecule library members (non-clinical, research-only):

• Such compounds are typically assessed for modulation of enzymes, receptors, transporters, or signaling pathways using in vitro or cell-based assays.
• Early observations often include potency (IC50/EC50), efficacy, and preliminary selectivity across a small target panel. These data are context-dependent and cannot be inferred without disclosure.
• Orthogonal profiling can include cell viability, off-target panels (e.g., hERG binding, cytochrome P450 interactions), and general PAINS/assay-interference filters to ensure signals are mechanism-based rather than artifactual.

Best practices:

• Confirm activity in at least two mechanistically distinct assays.
• Examine concentration–response with adequate replicates and include vehicle controls to isolate solvent effects.
• Evaluate baseline cytotoxicity and aggregation (e.g., detergent-sensitive shifts) to rule out nonspecific effects.

Note: No therapeutic claims are made; HB007 is for research use only. For any target-specific information, refer to the CoA, internal screening data, or contact support under appropriate data-sharing terms.

Buffer Applications

Buffering systems are not typically a property of the compound itself unless it is used as a buffer component. As HB007 is a small-molecule library member with undisclosed structure, there is no item-specific buffer role to report.

General guidance for preparing assay buffers with small-molecule additions:

• Maintain physiological pH (e.g., HEPES 20–25 mM pH 7.2–7.5 or PBS pH 7.4) unless the target requires otherwise.
• Keep final DMSO ≤0.5–1% v/v; prepare matched vehicle controls.
• Include low levels of non-ionic surfactant (e.g., 0.01–0.05% Tween-20/80) when aggregation is suspected and compatible with the assay.
• Filter (0.22 μm) and degas buffers for sensitive biophysical measurements (SPR, ITC) to reduce bubbles and baseline drift.

Because the acid/base properties of HB007 are unknown, avoid pH extremes and validate solubility/chemical stability across the intended assay pH range.

Green Alternatives

Without a disclosed structure for HB007, solvent and process choices cannot be tailored precisely. However, greener practice principles can still guide assay preparation and any follow-on chemistry.

Greener solvent hierarchy (general):

• Prefer water and biobased solvents where feasible for workups and dilutions.
• For stock solutions, if DMSO is required, minimize volumes and use high-purity grades to reduce impurities. Consider propylene carbonate or glycerol derivatives only where proven compatible with the assay.

Comparison (general, literature-based):

• DMSO vs 2-MeTHF/CPME: DMSO is typically for dissolution/assay delivery; 2-MeTHF/CPME are greener ethers useful for synthesis/extractions, not usually for biological dosing.
• ACN vs EtOH: Ethanol has a better environmental profile but may be less effective for highly lipophilic analytes; use at low percentages in assays.

Operational greening:

• Adopt miniaturized assay formats (384/1536-well) to cut solvent consumption and waste.
• Use closed, cold-chain logistics to extend shelf-life and reduce repeat shipments.
• Implement solvent recovery for method development and analytical runs.

Note: When the HB007 structure is available, solvent choice can be aligned with CHEM21/ACS GCI solvent guides to select the least hazardous option offering adequate performance.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or manufacturing use is specified for HB007. This product is supplied strictly for research use only and is not intended for human or veterinary use.

General considerations (non-therapeutic):

• Screening compounds may inform early discovery research. Any use in formulation development would require full disclosure of structure, impurity profile, salt form, and stability—none of which are provided here.
• If formulation-like studies are conducted in vitro (e.g., solubility screening), document solvent composition, pH, and any counter-ions to enable reproducibility.

Regulatory note:

• This product is not accompanied by pharmacopeial monographs and is not qualified as a GMP-grade material. Do not use in APIs, clinical materials, or diagnostics without appropriate requalification and regulatory oversight.

Physical Properties

Item-specific physical constants are not provided in this catalog entry.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point / Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density / Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• LogP/logD, pKa: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General guidance for small-molecule library members (literature/general):

• Compounds supplied for screening are commonly delivered as solids or pre-dissolved in anhydrous DMSO. If supplied as a solid, initial dissolution in dry DMSO to 10–50 mM is typical; further dilution into assay buffers (0.1–1% final DMSO) is common practice.
• If aqueous solubility is unknown, assess by tiered co-solvent addition (DMSO → DMSO/H2O or DMSO/buffer) and monitor for turbidity/precipitation. Gentle warming (≤40 °C) and sonication can aid dissolution when chemically appropriate.
• For compounds with ionizable groups, solubility may be improved by adjusting pH within 6.5–8.0 (biological assays) or by salt formation (for stock, where chemically stable).

Note: Without a disclosed structure, no computed or literature values can be ascribed specifically to HB007.

Quality and Grades

Item-specific grade and purity are not listed in this entry.

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

How to interpret grades (general guidance for small-molecule libraries):

• Screening compounds are typically supplied at >95% purity (HPLC/LC–MS) when intended for primary/secondary assays. Exact assay, chromatographic method, and detection wavelength should be verified on the CoA.
• Where stabilizers or counter-ions are used (e.g., HCl salt, TFA salt), this will be indicated on the CoA; these can influence solubility, hygroscopicity, and mass calculations.
• Batch-to-batch documentation usually includes: structure (if disclosed), formula, exact mass, analytical purity, residual solvents, and water content. When data are not in the catalog, request the latest CoA tied to the lot you will receive.

Practical recommendations:

• If critical for SAR or lead-optimization work, independently verify identity and purity on receipt (e.g., LC–MS, 1H NMR). Establish a retention sample at −80 °C.
• For low-mass samples, minimize freeze–thaw by preparing single-use aliquots immediately upon receipt, recording concentration and solvent lot.

Reaction and Applications

This product is categorized as a small-molecule/compound library member intended primarily for biological screening and chemical biology research, rather than as a synthetic reagent.

Item-specific reactivity data are not available.

General research applications for library compounds (non-clinical, non-therapeutic):

• In vitro screening: enzymatic assays, receptor binding, phenotypic cell assays, and target deconvolution workflows.
• Chemical biology probes (exploratory): once activity is observed, derivatives may be synthesized for SAR; HB007 can serve as an initial hit candidate pending structural disclosure.
• Biophysical methods: DSF/TSA, SPR, MST, NMR ligand-observe experiments to assess binding and stability effects.
• Profiling panels: ADME/Tox in vitro panels (microsomal stability, solubility, permeability) to characterize tractability.

Practical tips (general):

• Prepare concentrated DMSO stocks (10–50 mM); aliquot to avoid freeze–thaw cycles.
• Pre-clear insoluble particulates by brief centrifugation before dosing.
• Track compound plate maps meticulously; include vehicle and positive controls to benchmark assay performance.
• If hit-like behavior is observed, confirm purity and identity by orthogonal analytics (LC–MS, NMR) and run counter-screens to detect assay interference (e.g., aggregation, redox cycling, fluorescence quenching).

Reaction Conditions

No reaction-condition guidance can be given for HB007 specifically because its structure and functional groups are not disclosed.

General laboratory practices for handling unknown small-molecule solids/solutions:

• Keep solutions in anhydrous DMSO or compatible solvent at known concentration; avoid strong light and moisture until stability is confirmed.
• For any exploratory transformations (if structure is disclosed later), start with small-scale trials (≤0.05 mmol) and monitor by LC–MS to assess degradation pathways.
• Avoid extremes of pH, strong oxidants, or high temperatures until functional-group tolerance is known.

Analytical monitoring (general):

• Use LC–MS with orthogonal columns (C18, phenyl-hexyl) and 2–95% ACN/H2O + 0.1% formic acid gradients to track purity and detect non-UV-active impurities via MS.

Note: The primary intended use of this item is screening, not synthesis; see Application Protocols and Storage sections for practical guidance.

Safety and Handling

Safety data specific to HB007 are not provided in this entry; always consult the item’s SDS before use.

Item-specific info:

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / Pictograms: Not specified for this item; refer to SDS.
• Storage conditions: Store at −80 °C (per product data).
• Shipping: Ships on dry ice packs + cold packs (per product data).
• Research use: For research use only.

General laboratory handling guidance (not item-specific):

• Use a chemical fume hood for weighing and solution prep until volatility and hazard profile are known.
• Wear appropriate PPE: lab coat, safety glasses, and suitable gloves (e.g., nitrile). Change gloves frequently when handling DMSO stocks due to enhanced dermal penetration potential.
• Avoid inhalation of powders and aerosols; minimize dust formation; cap containers promptly to limit moisture uptake and oxidation.
• Incompatibilities and reactive hazards are unknown; segregate from strong oxidizers, strong acids/bases, and reducing agents until specific data are available.
• First aid (general): in case of skin contact, wash with soap and water; for eye exposure, rinse cautiously with water for several minutes; if inhaled, move to fresh air; if ingested, rinse mouth. Seek medical attention and bring SDS.

Waste disposal: Treat as organic laboratory chemical waste; follow institutional and local regulations.

Solvent Selection

No item-specific solubility or polarity data are provided. The following is general best practice for small-molecule screening compounds.

Primary solvent strategies:

• DMSO (anhydrous, ≥99.9%) is the default for initial stock solutions (10–50 mM) owing to broad solubilizing power and biological compatibility at ≤1% v/v in most assays.
• If DMSO is insufficient, consider co-solvents: DMF, acetonitrile, or mixed systems (e.g., DMSO/MeOH, DMSO/ACN). Transition to aqueous buffers gradually to avoid precipitation.
• For highly lipophilic chemotypes, tertiary stocks can be made in EtOH or PEG400 with subsequent dilution into buffer containing non-ionic surfactants (e.g., 0.01–0.05% Tween-80) if assay-compatible.

Assay buffer considerations:

• Maintain final DMSO ≤0.5–1% v/v to limit vehicle effects. Include matched vehicle controls.
• Filter sterilize aqueous working solutions (0.22 μm) when compatible and avoid adsorption to plastics by using low-bind tubes/plates for hydrophobic compounds.

Quick comparison (general):

• DMSO: highest breadth of solubilization; low volatility; enhances dermal absorption (use PPE).
• ACN: miscible with water; volatile; lower solvency for very lipophilic species.
• EtOH: bio-compatible up to ~0.5–1% v/v; may alter membrane interactions in cell assays.

Note: Confirm the chemical stability of HB007 in chosen solvent once the structure/CoA is available.

Storage and Reconstitution

Item-specific conditions from Product Data:

• Storage: Store at −80 °C.
• Shipped in: Dry ice packs + cold packs to maintain a continuous cold chain.

General best practices for small-molecule library members (not item-specific specifications):

• Upon receipt, verify the package temperature and immediately transfer the material to −80 °C storage. Record lot, receipt date, and condition.
• If supplied as a solid, keep desiccated and protected from light. If supplied in DMSO, minimize headspace to reduce moisture uptake; consider overlaying with dry inert gas for long-term storage.
• Prepare single-use aliquots to avoid repeated freeze–thaw cycles that can accelerate degradation and concentration drift (via moisture ingress or precipitation).
• For reconstitution, use anhydrous DMSO as a first-line solvent unless the CoA specifies otherwise. Typical initial concentrations are 10–50 mM. Mix thoroughly and confirm complete dissolution before making aqueous dilutions.
• For aqueous working solutions, use freshly prepared dilutions and keep on ice or at 4 °C during the assay. Discard after the experiment unless stability is confirmed experimentally.

Labeling and documentation:

• Clearly label aliquots with compound ID (HB007), concentration, solvent, preparation date, and storage temperature. Maintain an electronic inventory with location and freeze–thaw history.

Note: Any unstated specifications (water content, purity, stabilizers) are not specified for this item; refer to the CoA/Spec Sheet.

Structure and Identity

Brief overview: HB007 (SKU H655911) is listed in our small-molecule/compound library category. Item-specific structural identifiers are not disclosed in this listing.

• Product name: HB007
• SKU: H655911
• CAS: 2387821-46-5 (registry only; structure not provided here)
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Synonyms/Code names: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general note):

• Because no structure is provided, functional groups, ring systems, and stereochemistry cannot be summarized for this specific item. For definitive structural identity (2D/3D), please consult the product’s Certificate of Analysis (CoA), Specification Sheet, or request the structure disclosure (where available under appropriate agreements).

Synthetic Utility

HB007 is listed as a small-molecule library member with undisclosed structure; it is not presented as a synthetic building block or reagent. Therefore, item-specific synthetic transformations, functional-group reactivity, or named-reaction applicability cannot be provided.

General notes (when repurposing screening compounds in synthesis):

• If structure becomes available and the compound contains common handles (e.g., aryl halide, boronate, amine, carboxylate), standard cross-coupling, amide coupling, or protection–deprotection strategies may be applicable to generate analogs for SAR.
• Prior to synthetic use, confirm availability of gram-scale material and assess stability under typical reaction conditions (base/acid, oxidants/reductants, temperature).
• For impurity control, reproduce the supplier’s analytical methods (HPLC, LC–MS) and establish orthogonal ID (1H/13C NMR) before derivatization.

If your intended use is synthetic rather than screening, please contact us about structure disclosure or alternate building-block forms.

Target Specificity

Target specificity information (e.g., named protein, pathway, or binding site) is not provided for HB007 in this listing.

• Item-specific target/epitope/assay validations: Not specified for this item; refer to CoA/Spec Sheet or internal screening data.

General recommendations:

• If HB007 is used in screening, follow up any activity with selectivity panels (closely related isoforms/family members) and orthogonal assays to confirm on-target effects.
• Employ counter-screens for PAINS/interference liabilities (aggregation, redox activity, fluorescence interference) to avoid false positives.

For target disclosure or collaboration requests, contact Aladdin Scientific with your intended application; additional data may be available under appropriate agreements.

Häufig gestellte Fragen

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2387821-46-5, the molecular formula is C15H9ClN4OS, and the molecular weight is 328.78 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.